The Effect of Lifestyle-Adjustments Prior to Medical Treatment on the Effect of Medical Treatment in Reflux Patients

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00524251
First received: August 29, 2007
Last updated: September 16, 2008
Last verified: September 2008
  Purpose

The purpose of this study is to determine whether the improvement in the quality of life after an initial treatment with esomeprazole 40mg for reflux disease is the same in patients who have already made lifestyle-adjustments as in patients who have not implemented lifestyle-adjustments prior to the start of treatment (baseline)


Condition Intervention
GERD
Quality of Life
Drug: esomeprazole

Study Type: Observational
Study Design: Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Estimated Enrollment: 990
Study Start Date: June 2004
Study Completion Date: March 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with reflux complaints
  • 18 years of age

Exclusion Criteria:

  • Restrictions as mentioned in the registration text
  • H2RA or PPI use in the month prior to inclusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00524251

  Hide Study Locations
Locations
Netherlands
Research Site
Almere, Netherlands
Research Site
Apeldoorn, Netherlands
Research Site
Baarn, Netherlands
Research Site
Bennebroek, Netherlands
Research Site
Blaardingen, Netherlands
Research Site
Boekel, Netherlands
Research Site
Bunschoten Spakenburg, Netherlands
Research Site
Delft, Netherlands
Research Site
Den Haag, Netherlands
Research Site
Enschede, Netherlands
Research Site
Ewijk, Netherlands
Research Site
Geleen, Netherlands
Research Site
Haelen, Netherlands
Research Site
Halfweg NH, Netherlands
Research Site
Hardenberg, Netherlands
Research Site
Heemstede, Netherlands
Research Site
Hillegom, Netherlands
Research Site
Hilversum, Netherlands
Research Site
Horst, Netherlands
Research Site
Kerkrade, Netherlands
Research Site
Klimmen, Netherlands
Research Site
Landgraaf, Netherlands
Research Site
Laren, Netherlands
Research Site
Leusden, Netherlands
Research Site
Lichtenvoorde, Netherlands
Research Site
Lisse, Netherlands
Research Site
Maastricht, Netherlands
Research Site
Monster, Netherlands
Research Site
Nieuw Vennep, Netherlands
Research Site
Nieuwegein, Netherlands
Research Site
Nijverdal, Netherlands
Research Site
Ochten, Netherlands
Research Site
Oisterwijk, Netherlands
Research Site
Oldenzaal, Netherlands
Research Site
Pijnacker, Netherlands
Research Site
Rijnsburg, Netherlands
Research Site
Rijssen, Netherlands
Research Site
s-Gravenzande, Netherlands
Research Site
Schijndel, Netherlands
Research Site
Sittard, Netherlands
Research Site
Soest, Netherlands
Research Site
Susteren, Netherlands
Research Site
Swalmen, Netherlands
Research Site
Tilburg, Netherlands
Research Site
Vaals, Netherlands
Research Site
Valkenburg, Netherlands
Research Site
Veenendaall, Netherlands
Research Site
Velp, Netherlands
Research Site
Warnsveld, Netherlands
Research Site
Wassenaar, Netherlands
Research Site
Westerhaar-Vrienzenv Wijk, Netherlands
Research Site
Zandvoort, Netherlands
Research Site
Zevenhuizen, Netherlands
Research Site
Zoetermeer, Netherlands
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: A Sellink, MD AstraZeneca
Study Chair: N van den Berk AstraZeneca
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00524251     History of Changes
Other Study ID Numbers: N11
Study First Received: August 29, 2007
Last Updated: September 16, 2008
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by AstraZeneca:
Patients with reflux complaints
GERD
quality of life
lifestyle adjustments

Additional relevant MeSH terms:
Esomeprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Therapeutic Uses
Pharmacologic Actions
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on October 01, 2014